1. Home
  2. Live Updates
  3. First Safety and Efficacy Data of Rakuten Medical's Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023 : vimarsana.com

First Safety and Efficacy Data of Rakuten Medical's Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023 : vimarsana.com

First Safety and Efficacy Data of Rakuten Medical's Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023

/PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its...

Related Keywords

Switzerland , Taiwan , United States , India , Japan , Texas , Netherlands , Japanese , American , Annm Gillenwater , Hisataka Kobayashi , Mickey Mikitani , Division Of Surgery , Neck Society , International Conference On Head , National Cancer Institute , Rakuten Medical Inc , Japanese Ministry Of Health , Drug Administration , University Of Texas Md Anderson Cancer Center , Department Of Head , Rakuten Medical , American Head , International Conference , Neck Cancer , Neck Surgery , Cancer Center , Fast Track , Japanese Ministry , Sakigake Designation System , Conditional Early Approval , Nc ,

© 2024 Vimarsana